Patents by Inventor Walter C. Soeller

Walter C. Soeller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulating ramp activity
    Patent number: 6927317
    Abstract: The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a disrupted RAMP1, RAMP2, or RAMP3 gene. Also provided by the invention are methods of screening for agents that modulate the activity or expression of a RAMP and methods of treating mammals to modulate liver function and/or muscle metabolism.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: August 9, 2005
    Assignee: Pfizer, Inc.
    Inventors: John D. McNeish, Walter C. Soeller, John F. Thompson
  • Modulating ramp activity
    Publication number: 20020178459
    Abstract: The invention provides genetically-modified non-human mammals and genetically-modified animal cells containing a disrupted RAMP1, RAMP2, or RAMP3 gene. Also provided by the invention are methods of screening for agents that modulate the activity or expression of a RAMP and methods of treating mammals to modulate liver function and/or muscle metabolism.
    Type: Application
    Filed: November 30, 2001
    Publication date: November 28, 2002
    Inventors: John D. McNeish, Walter C. Soeller, John F. Thompson
  • Transgenic animal models for type II diabetes mellitus
    Patent number: 6187991
    Abstract: The generation of transgenic animal models for testing various treatments of Type II Diabetes Mellitus are described. The DNA construct allows pancreatic &bgr; cell-specific expression of human islet associated polypeptide (IAPP) under the regulation of the rat insulin II promoter in both cell lines and transgenic animals. The DNA construct is introduced into animal embryos by microinjection as one or multiple copies or into established cell lines by electroporation. The transgenic animals develop amyloid plaque deposits in the islets of Langerhans in the pancreas, fasting hyperglycemia, glycouria and diabetic glomerulosclerosis at 3 to 5 months of age. The cell lines can be screened for treatments that inhibit expression of human IAPP; the transgenic animals can be screened for treatments that either enhance or inhibit the progression of this disease phenotype.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 13, 2001
    Assignee: Pfizer Inc
    Inventors: Walter C. Soeller, Maynard D. Carty, David K. Kreutter